最新临床研究数据显示，Welireg®（Belzutifan）与Lenvima®（Lenvatinib）的联合疗法，在特定既往接受过治疗的晚期肾细胞癌患者群体中展现出显著优势。与使用卡博替尼的治疗方案相比，该联合疗法能够将疾病进展或死亡的风险显著降低30%。这一结果凸显了该组合疗法在改善晚期肾细胞癌患者临床结局方面的潜力。
最新临床研究数据显示，Welireg®（Belzutifan）与Lenvima®（Lenvatinib）的联合疗法，在特定既往接受过治疗的晚期肾细胞癌患者群体中展现出显著优势。与使用卡博替尼的治疗方案相比，该联合疗法能够将疾病进展或死亡的风险显著降低30%。这一结果凸显了该组合疗法在改善晚期肾细胞癌患者临床结局方面的潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.